Trading Update

One Health Group plc
("One Health", the "Company" or the “Group”)
Trading Update
H1 27 Revenue and EBITDA significantly ahead of prior year
Strong growth across all KPIs
One Health Group plc (AIM: OHGR), the independent provider of NHS-funded surgical procedures for patients referred from the NHS through ‘Patient Choice’, provides the following trading update for the six months to 30 September 2026 (“H1 27”), showing strong growth across key operational performance indicators, in-line with management expectations.
Key Highlights
|
|
H1 27
|
H1 26
|
Change
|
|
Revenue |
£18.3m |
£15.6m |
+17% |
|
New NHS patient referrals |
11,275 |
9,111 |
+24% |
|
Number of consultations |
29,755 |
23,927 |
+24% |
|
Number of surgical procedures |
4,517 |
4,009 |
+13% |
|
Number of consultants (excluding anaesthetists)* |
82 |
80 |
+3% |
|
Annualised revenue per consultant (k) |
446 |
391 |
+17% |
|
Number of Outreach Clinics |
46 |
40 |
+15% |
|
Number of Surgical Operating Facilities |
14 |
12 |
+17% |
* Consultant pool has been rationalised since March 2026 (88) to drive higher productivity, a further 12 consultants are under review in the talent pipeline to support future continued growth
- Underlying EBITDA for H1 27 is expected to be ahead of the £1.18 million reported for H1 FY26, reflecting increased activity and continued operational progress across the Group.
- Activity during H1 27 was ahead of both the corresponding period last year and H2 26. This reflects continued growth in patient referrals and management’s focus on delivering activity earlier in the financial year, providing greater resilience against potential disruption to NHS commissioning during the second half.
- Demand for additional elective capacity from the independent sector is expected to remain an important part of the NHS response to the national waiting list, which increased from approximately 7.1 million in March 2026 to 7.3 million in May 2026 and had risen to approximately 7.4 million in August 2026.
Surgical Hub
- Construction of the Group’s first surgical hub is progressing well, as detailed in the recent AGM Statement, with the shell now weather-tight, and is expected to open in Spring 2027. Further details are available on the Company website: https://www.onehealth.co.uk/news/one-perspective---hub-progress
- Once operational, the hub is expected to deliver a significant increase in the surgical capacity available to the Group in an area characterised by strong NHS patient demand and limited existing capacity.
- A further potential site has been identified for more detailed preliminary assessment as a possible location for the Group’s second surgical hub. The Group is also making good progress in identifying additional sites capable of supporting its longer-term development strategy.
Outlook
The Board remains confident in the Group’s growth prospects. Based on trading during the first half and the current outlook, the Group remains on track to deliver expected revenue growth and underlying EBITDA for FY27, both in line with current market expectations1.
The abolition of NHS England (“NHSE”) and transfer of its functions into the Department of Health and Social Care was announced by Sir Keir Starmer in March 2025. Subject to Parliamentary approval, the reorganisation is expected to be completed by March 2027. The associated changes, including significant reductions in administrative and commissioning roles across NHSE and Integrated Care Boards (“ICBs”), may create some short-term disruption to local commissioning processes. The Company’s strong first-half performance, diverse referral routes and established relationships across the NHS, provide stability and resilience for the Company as these changes are implemented.
Historically, the Group has experienced an increase in NHS activity during the final quarter of the financial year as NHS organisations seek to meet year-end operational and waiting-list objectives. Although this additional activity is neither contracted nor guaranteed, the Board believes that significant waiting-list pressures continue to support the Board’s confidence in delivering growth in line with market expectations.
One Health will announce its half-year results in late November 2026, and a notice of results will be announced in due course.
1Management understands market consensus for revenue and underlying EBITDA for FY27 to be £33.2 million to £34.0 million and £2.6 million respectively.
Adam Binns, Chief Executive Officer, commented:
“The continued dedication and commitment of our team, building on the strong performance and momentum achieved last year, have enabled One Health to deliver another positive first half. Activity was ahead of both the corresponding period last year and the second half of FY26, with growth achieved across all key performance measures.
“The number of patients choosing One Health following referral by their GP continues to increase. This reflects growing public awareness of NHS Patient Choice and patients’ right to choose a local provider offering high-quality secondary care, free at the point of delivery, with shorter waiting times. The quality of care provided to our patients remains central to everything we do. Post-operative patient feedback averaged 99% positive during the first six months of the year, an exceptional result that reflects the dedication, expertise and compassion of our clinical and operational teams.
“The national referral-to-treatment waiting list remains extremely high and continues to rise on a monthly basis, with approximately 7.4 million pathways in August 2026, and around 111,000 pathways involving waits of more than one year. This underlines the continuing need for additional elective capacity and the important role trusted independent-sector providers can play in supporting the NHS. Alongside continued growth in GP referrals, we anticipate opportunities for additional NHS Trust activity during the second half as local trusts seek to address waiting-list pressures and meet year-end performance objectives. This activity is not contracted or guaranteed, but has historically provided an additional source of demand during the final quarter.
“Having provided high-quality care in partnership with the NHS for more than 22 years, we look to the future with confidence. One Health remains well positioned to deliver continued growth while providing much-needed care, free at the point of delivery, to NHS patients across an expanding geographic footprint.”
If you wish to keep up to date on Company news please email: onehealth@walbrookpr.com
This announcement contains inside information for the purposes of the UK Market Abuse Regulation
and the Directors of the Company are responsible for the release of this announcement.
For more information, please contact:
|
One Health Group plc Derek Bickerstaff, Chairman Adam Binns, CEO
|
Via Walbrook PR |
|
|
Panmure Liberum (Nominated Adviser and Broker) Emma Earl, Will Goode, Mark Rogers Rupert Dearden
|
Tel: +44 (0)20 3100 2000 |
|
|
Walbrook PR (Media & Investor Relations) Alice Woodings, Paul McManus, Rachel Broad |
Tel: +44 (0)20 7933 8780 or onehealth@walbrookpr.com Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893 +44 (0)7747 515 393 |
|
|
|
|
|
|
|
||
About One Health Group plc (www.onehealth.co.uk)
Last year One Health engaged 88 NHS Consultants (excluding anaesthetists) who sub-specialise in the various surgeries offered by the Company, through a growing network of community-based outreach clinics and surgical operating locations. One Health continues to deliver strong growth and, in the year, to March 2026 provided much needed care to almost 19,000 new patients, through over 50,000 consultations and over 8,000 surgical procedures. One Health deploys surgeons and anaesthetists that are mostly employed by the NHS, on a subcontracted basis. It currently works with over 140 professionals across 14 independent hospitals and 40 outreach clinics. Within these community-based outreach clinics all consultations and post-operative physiotherapy is delivered where required, reducing patient inconvenience, excess travel and distress.
One Health's activities are focused on areas where NHS patient needs are under-supplied by the local NHS service, population density is relatively high and the level of private medical insurance or the ability to self-fund is relatively low. Currently, the Company's activities are focused in Yorkshire, Lincolnshire, Derbyshire, Nottinghamshire and Leicestershire. Revenue is derived from 29 ICBs across England as well as contracts with local NHS trusts to transfer their internal waiting list patients to One Health for quicker treatment. One Health's business model has focused to date on four main areas: orthopaedics, spine, general surgery and gynaecology, which represent the majority of the national waiting list, with urology introduced at the end of FY25.
Spine and orthopaedics are particularly attractive areas for One Health as the Directors believe that they benefit from powerful growth drivers in terms of an ageing demographic, physical inactivity and an increasing proportion of the population being categorised as obese. Within orthopaedics, the most common surgeries performed by One Health are knee and hip replacements.
Online investor presentation
Click below for the latest online presentation by Derek Bickerstaff, Chairman and Adam Binns, Chief Executive Officer, which offers insights into the Company’s financial results for the year ended 31 March 2026, growth strategy and long-term vision: https://www.investormeetcompany.com/meetings/investor-presentation-1068
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE